A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of oral capecitabine (Xeloda) versus
5-fluorouracil (5-FU), in combination with intravenous (IV) cisplatin, in participants with
advanced and/or metastatic gastric cancer. The anticipated time on study treatment is at
least 6 weeks and continued up to disease progression, and the target sample size is 300
individuals.